Nymox Pharmaceutical Corp. (NYMX) on Monday released positive new clinical trial data from responder analysis of its pooled multi-center U.S. Phase 2 studies of NX-1207, indicating durable early responder benefits from Nymox's innovative drug treatment for benign prostatic hyperplasia or BPH.
The study concerned patients who reported a 6 point or better improvement in BPH Symptom Score improvement within a month of treatment. At follow-up, that is 14 months on average post-treatment, proportionally there were over 4.3 times as many NX-1207 early responders who had maintained a 6 point or better improvement in symptom score and who did not require further BPH treatment of any kind as compared to placebo controls.
NX-1207 is a novel drug developed by Nymox which is in Phase 3 development for the treatment of BPH. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where it has been found to produce improvements that are about double that reported for currently approved BPH drugs. NX-1207 is administered by a urologist in an office procedure that takes only a few minutes and involves little or no pain or discomfort.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.